₩314,000.00
-3500.00 (-1.10%)
KRW · as of 2026-08-14 · marketstack
stale — last close 2026-08-14, not a live quote
Clinical trials
catalyst calendar across sponsors →Studies where 196170.KQ is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy VolunteerNCT05232175results2026-01-29Incidence Rate of Drug Allergy Following ID Injection of the IPRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: ALT-BB4, 0.9%NaCl | Health, Subjective | 290 | 2022-08-24actual | 2026-01-29 |
| Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMDNCT04058535Occurrences of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: Eylea, ALT-L9 | Neovascular Age-related Macular Degeneration | 28 | 2020-12-22actual | 2022-01-20 |
| Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer PatientsNCT03281824DLT testOpen-label · Other | Phase 1 | Completed | Biological: ALT-P7 (HM2-MMAE) | HER2-positive Breast Cancer | 27 | 2020-03-12actual | 2022-01-18 |
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy SubjectsNCT03242239AUC0-inf: area under the concentration-time curve from time zero to infinityRandomized · Double-masked · Treatment | Phase 1 | Completed | Biological: ALT02, EU-licensed Herceptin, US-licensed Herceptin | Healthy | 105 | 2016-08-04actual | 2017-08-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19